Foley T P, Owings J, Hayford J T, Blizzard R M
J Clin Invest. 1972 Feb;51(2):431-7. doi: 10.1172/JCI106829.
Synthetic thyrotropin-releasing hormone (TRH) was administered intravenously in a dose of 7 mug/kg to 20 normal children ages 4-13 yr. Serum thyroid-stimulating hormone (TSH) was measured by radioimmunoassay and rose from a mean value of 1.7 muU/ml (range = < 1.25-7.2) to a mean peak value of 21.5 muU/ml (5.2-33.2) at 15 or 30 min after administration.13 patients with idiopathic hypopituitarism and apparent normal thyroid function, ages 3-19 yr, responded to TRH in a manner very similar to the control subjects: TSH rose from a mean value of 1.8 muU/ml (range < 1.25-4.3) to a mean peak value of 18.5 muU/ml (range = 9.5-45.0) which occurred between 15 and 60 min after TRH.13 idiopathic hypopituitary patients with documented thyroid deficiency were tested after thyroid therapy had been discontinued for a minimum of 10 days. The serum TSH values in 10 of 13 patients rose from a mean base line level of 2.2 muU/ml (< 1.25-5.3) to a peak mean value of 32.5 muU/ml (9.6-61.3) between 30 and 120 min after TRH. In three patients, however, little or no TSH response was detected, even when serum thyroxine levels were extremely low. Similar to the latter group, three of five patients with hypopituitarism secondary to craniopharyngiomas had undetectable or barely measurable TSH levels before and after TRH. Two of these five patients had significant responses which were compatible with hypopituitarism resulting from damage to the hypothalamus or hypothalamic vessels instead of the pituitary. Side effects were experienced in 41 of 54 patients (76%). The effects were limited to a mild nausea-like sensation in 63% of the patients and occurred within the first 5 min after receiving TRH. No evidence of serious toxicity or long-term side effects was noted. The TRH test is a safe, effective way to measure TSH reserve in children. The positive response in 10 of 13 patients with secondary hypothyroidism supports data previously accumulated that most patients with idiopathic hypopituitarism have an abnormality of their hypothalamic-releasing hormone function, whereas the remaining minority probably have primary pituitary disease.
对20名4至13岁的正常儿童静脉注射剂量为7微克/千克的合成促甲状腺激素释放激素(TRH)。通过放射免疫分析法测定血清促甲状腺激素(TSH),给药后15或30分钟时,其均值从1.7微单位/毫升(范围为<1.25至7.2)升至平均峰值21.5微单位/毫升(5.2至33.2)。13名年龄在3至19岁、患有特发性垂体功能减退且甲状腺功能明显正常的患者,对TRH的反应与对照组非常相似:TSH均值从1.8微单位/毫升(范围<1.25至4.3)升至平均峰值18.5微单位/毫升(范围为9.5至45.0),出现在TRH给药后15至60分钟之间。13名有记录的甲状腺功能减退的特发性垂体功能减退患者,在甲状腺治疗停药至少10天后接受测试。13名患者中有10名的血清TSH值在TRH给药后30至120分钟之间,从平均基线水平2.2微单位/毫升(<1.25至5.3)升至峰值平均值32.5微单位/毫升(9.6至61.3)。然而,在3名患者中,即使血清甲状腺素水平极低,也未检测到TSH反应或反应极小。与后一组相似,5名颅咽管瘤继发垂体功能减退的患者中有3名在TRH前后TSH水平检测不到或几乎无法测量。这5名患者中有2名有明显反应,这与下丘脑或下丘脑血管受损而非垂体受损导致的垂体功能减退相符。54名患者中有41名(76%)出现了副作用。63%的患者副作用仅限于轻微的类似恶心的感觉,且在接受TRH后的前5分钟内出现。未发现严重毒性或长期副作用的证据。TRH试验是一种安全、有效的测量儿童TSH储备的方法。13名继发性甲状腺功能减退患者中有10名出现阳性反应,这支持了先前积累的数据,即大多数特发性垂体功能减退患者下丘脑释放激素功能异常,而其余少数患者可能患有原发性垂体疾病。